Scarica l'app Stockscreener
3.50
5.66%
-0.21
Dopo l'orario di chiusura:
3.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
Gene Therapy Market Set for Strong Growth with Ongoing Rare - openPR.com
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Yahoo Finance
Learn to Evaluate (BLUE) using the Charts - news.stocktradersdaily.com
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BLUE - ACCESS Newswire
Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - BioSpace
Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio - marketscreener.com
bluebird bio nears acquisition by Carlyle and SK Capital - Investing.com
Bluebird Bio (BLUE) Nears Acquisition Completion Following Regulatory Approvals | BLUE Stock News - GuruFocus
bluebird bio Inc expected to post a loss of $3.69 a shareEarnings Preview - TradingView
Investors Who Lost Money on Bluebird Bio, Inc. (BLUE) Should Contact Levi & Korsinsky About Pending Class Action – BLUE - ACCESS Newswire
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc.(BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Sickle Cell Disease Treatment Market Set to Witness Significant - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cell And Gene Therapy Manufacturing Market Is Booming So Rapidly 2025-2032 -Bluebird Bio Inc., Lonza, Catalent Inc. - openPR.com
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Lost Money on bluebird bio, Inc.(BLUE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):